arznei-telegramm Logo a-t Kurzlogo
    ❮ a-t 2/2017 a-t ❯
    This is a translation of the table of contents. One article of each issue is translated and freely available.
    table of contents
    SPOT ON

    Post-marketing trials without tangible benefit

    NEW ON THE MARKET

    Anti-interleukin-5 antibody reslizumab (CINQAERO) for severe eosinophilic asthma

    THERAPY FROM A CRITICAL VIEWPOINT

    Delirium in palliative care: neuroleptics worse than placebo

    Tapentadol (PALEXIA, YANTIL): What

    IN BRIEF

    Migraine prevention in children: is placebo the best medicine?

    Death following overdose of colchicine - the package size of the drop formulation is to be limited

    France: zolpidem (STILNOX, generics) -narcotic prescription required

    Glucosamine and chondroitin in osteoarthritis without benefit in yet another study

    CURRENT ADR NETWORK REPORT

    Urticaria with apixaban (ELIQUIS)

    SIDE EFFECTS

    Malformations with hydroxyethylrutoside (e.g. VENORUTON)?

    Fatalities with selexipag (UPTRAVI) in pulmonary hypertension

    Rivaroxaban (XARELTO): agranulocytosis and STEVENS-JOHNSON syndrome
    free

    e a-t ON THE INTERNET

    Elbasvir plus Grazoprevir (ZEPATIER) for hepatitis C

    Amputations with SGLT2 inhibitors

    Once more: anaphylactic reactions with chlorhexidine

    arznei-telegramm

    Independent drug information – in English

    Concise, critical evaluations of drugs and medical devices for evidence-based therapy and patient advice on benefits and risks – independent, ad-free and funded exclusively by subscriptions.

    Browse free articles